Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and
recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a …

A novel series of macrocyclic FXIa inhibitors was designed based on our lead acyclic phenyl
imidazole chemotype. Our initial macrocycles, which were double-digit nanomolar FXIa …

The management of asymptomatic atherosclerotic carotid artery disease and the role of
antithrombotic therapy is of increasing importance for stroke prevention. Non-invasive …

Objectives To investigate temporal trends in the use of non-vitamin K oral anticoagulants
(NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in …

Nonvitamin K antagonist oral anticoagulants (NOACs) have emerged as the preferred
choice for the treatment of atrial fibrillation (AF). The establishment of a therapeutic range to …

Abstract Ethnopharmacological relevance Chuanxiong Rhizoma (rhizomes of Ligusticum
chuanxiong Hort), known as Chuanxiong in Chinese, has been used for treating …

Optimization of macrocyclic inhibitors of FXIa is described which focused on modifications to
both the macrocyclic linker and the P1 group. Increases in potency were discovered through …

Objetivos El 40% de los pacientes con fibrilación auricular no valvular (FANV) que reciben
antagonistas de la vitamina K (AVK) en atención primaria (AP) en España presentan un mal …

Background Atrial fibrillation (AF) ablation with minimally interrupted direct oral
anticoagulants (DOACs) predominates, possibly raising concern about their remaining …

A series of macrocyclic factor XIa (FXIa) inhibitors was designed based on an analysis of the
crystal structures of the acyclic phenylimidazole compounds. Further optimization using …